Il-Yang Pharm. Co., Ltd.   Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: Gyeonggi-do Korea, Republic of (1946)
Status: No NME R&D (1946)

Organization Overview

First Clinical Trial
2005
NCT01820143
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

IL-YANG Pharmaceutical.Co.,Ltd. | IL-YANG Pharmaceutical Co.LTD | IL-YANG Pharmaceutical. Co., LTD | Il-Yang Pharm. Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bone Marrow Diseases (Phase 3)

Communicable Diseases (Phase 4)

Esophagitis (Phase 3)

Gastroesophageal Reflux (Phase 3)

Gastrointestinal Hemorrhage (Phase 4)

Helicobacter Infections (Phase 4)

Hematologic Diseases (Phase 3)

Infections (Phase 4)

Influenza, Human (Phase 3)

Leukemia (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Chronic-Phase (Phase 3)

Peptic Ulcer (Phase 3)

Philadelphia Chromosome (Phase 3)

Stomach Neoplasms (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial APIs: 14